Intra-Cellular Therapies, Inc. (ITCI)
| Previous close | 71.21 |
| Open | 71.12 |
| Bid | 68.42 x 100 |
| Ask | 68.66 x 100 |
| Day's range | 68.56 - 71.22 |
| 52-week range | 45.50 - 84.89 |
| Volume | |
| Avg. volume | 977,113 |
| Market cap | 7.257B |
| Beta (5Y monthly) | 1.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.46 |
| Earnings date | 01 Aug 2024 - 05 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 91.64 |
GlobeNewswireIntra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate in two upcoming investor conferences: 2024 RBC Capital Markets Global Healthcare ConferenceTuesday, May 14, 2024 at 10:00 a.m. ET in New York, NY Bank of America Healthcare Conference 2024Thursday, May 16, 2024 at 9:20 a.m. PT (12:2
- GuruFocus.com
Intra-Cellular Therapies Inc (ITCI) Q1 2024 Earnings Call Transcript Highlights: Robust Revenue ...
Explore key financial achievements and strategic directions from Intra-Cellular Therapies' first quarter of 2024, including a significant revenue increase and promising drug development updates.
- GuruFocus.com
Intra-Cellular Therapies Surpasses Q1 Revenue Estimates with Strong CAPLYTA Sales
Robust Growth and Positive Clinical Results Propel Forward Momentum
